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ABSTRACT
Taylor, Jacob Michael. MS Clinical Nutrition. The University of Memphis.
Dec./2010. Obesity and Acute Lymphocytic Leukemia. Major Professor:
Margaret R. Williams
Obesity rates for pediatric acute lymphocytic leukemia (ALL) survivors vary from
11%-57%. The purpose of this study was to evaluate the relationship between
caloric and macronutrient intake on the incidence of obesity in survivors of
pediatric ALL. A retrospective study of 137 participants using existing data
collected from the Bone II study was evaluated. Participants were grouped into
categories based on BMI for adults and CDC growth charts for children. Data
was collected from 24 hour food recalls at time of enrollment. No statistical
significance was found between BMI groups. Forty percent of participants were
overweight or obese, but 69% were below the DRI for calorie intake. Half the
participants consumed above the AMDR for percentage of calories from fat and
96% of participants consumed above the AMDR for percentage of calories from
sugar. Based on these findings there is no association between obesity status
and caloric and macronutrient intake.
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CHAPTER I
REVIEW OF LITERATURE
Introduction
Adult obesity rates are increasing rapidly with rates in many states
doubling and tripling since 1989. Childhood obesity is following a similar trend
with obesity rates increasing from 6.5% in 1980 to 17% in 2006 (1). Obesity is
linked with several health-related consequences including cardiovascular
disease, asthma, hepatic steatosis, sleep apnea, diabetes, and psychosocial
risks such as early and systemic social discrimination (1). As a way to combat
the widespread prevalence of obesity, many health-focused, obesity prevention
programs have been implemented by public health organizations. However, one
group often not considered are those with acute or chronic illness, particularly
those with childhood illnesses. Obesity rates for pediatric acute lymphocytic
leukemia (ALL) survivors vary from 11%-57% (2). In these survivors, obesity
compounds the known increased risks for developing type 2 diabetes,
hypertension, dyslipidemia, glucose intolerance, and secondary cancers later in
life (2). Survivors of ALL often have low self-esteem and depression that may be
negatively impacted by increased body weight. While there is conflicting
evidence, Withycombe et al. (2) showed that children with ALL who are obese at
the time of diagnosis exhibited a higher probability of relapse than those who
were of normal weight at diagnosis. Treatment advancements of cancer have
resulted in a growing population of survivors in whom long-term consequences
are now becoming apparent. To clearly understand the factors that affect the
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incidence of obesity in this population, we investigated multiple factors present
before, during, and after treatment.
Before Diagnosis
Researchers have sought to identify potential indicators of obesity existing
before diagnosis of ALL. One study enrolled 54 pediatric ALL patients who were
treated with chemotherapy alone (3). The investigators found that 48% of ALL
survivors were overweight or obese 5 years after diagnosis as compared to the
general population where 21% were overweight or obese. They found that BMI at
time of diagnosis and maternal BMI were significant factors that may predict
greater weight gain after disease remission (3). Razzouck and colleagues (4)
reported similar results; individuals who were overweight or obese at diagnosis
were 9.2 times more likely to be overweight or obese when they reached adult
height and 14.7 times more likely to be obese as compared to patients who were
normal weight at diagnosis. Gofman and Ducore (5) enrolled 95 patients aged 18
years or older at diagnosis and free from disease for 2 years after treatment.
They investigated the association of age at diagnosis, gender, race, median
treatment, central nervous system disease and radiation, radiation field, and
metabolic history including antihypertensive medications, hyperglycemia, and
thyroid disease with obesity. Based upon BMI at time of diagnosis, 6% of
participants were overweight and 2% were obese. At the end of treatment, 20%
were overweight and 12% were obese. Follow-up was performed 2 years after
completion of therapy revealed that 16% of patients were overweight and 24%
were obese. Thus, patients gained weight during treatment for ALL at a rate
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similar to weight gain seen in the non-ALL pediatric population. Of the patients
who survived for 3 years after completion of therapy, 24% were obese which is
equivalent to the obesity rate seen in the United States population as a whole (1).
The only factors found to be significant in predicting obesity at diagnosis were
younger age at diagnosis (participants ages ranged from six months to16.7
years), BMI at diagnosis, and Hispanic race (5). These studies showed that
factors that impact the incidence of obesity in ALL survivors exists even prior to
diagnosis.
During and After Treatment
Identification of factors associated with weight gain during and after
treatment have similarly been sought in an attempt to develop interventions to
modify weight gain. One study examined whether or not drug therapy alone
during treatment was associated with an increase in weight gain and
hypertension in ALL patients (6). Similar to the predictors of obesity present
before diagnosis, the study results indicated that those who were younger at
diagnosis, female, and overweight or obese at baseline were at higher risk for
obesity later in life. A unique finding from this study was that most of the weight
gained during treatment was maintained over time. At the end of therapy, 38.2%
were overweight/obese and 41.2% were overweight/obese 5 years from
diagnosis as compared to 23.6% at diagnosis. Since corticosteroid dose was
associated with increased BMI z-scores, researchers concluded that
corticosteroids given during treatment were the main factor associated with
obesity at follow-up (6).
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Additional studies identified other factors of ALL treatment on obesity.
Garmey et al. (7) compared pediatric ALL survivors to childhood cancer survivor
siblings and found that BMI increased 2.7 units and 1.7 units in females and 2.2
units and 1.5 units in males from baseline to completion of follow-up (mean of 7.8
years), respectively. Though BMI increased from baseline in both groups, only
the ALL group treated with cranial radiation therapy (CRT) showed a significant
increase in BMI over the control group (p<.01). Furthermore, the younger the
patient at the time when radiation was given, the more weight they gained over
time (7). However, other studies such as Withycombe and colleagues (2) were
unable to show treatment with CRT to be a valid predictor of increased BMI.
Since the acquisition and distribution of fat in patients receiving CRT have
been linked to increased BMI, investigators assessed the association of CRT and
gender, with abdominal adiposity, liver fat, and muscle composition (8).
Researchers concluded that despite having similar BMI and waist circumference,
the survivors treated with CRT had a greater amount of abdominal and visceral
fat compared to survivors treated with chemotherapy alone. Subcutaneous
abdominal fat was similar in amount and distribution in CRT and non-CRT
survivors. The distribution of fat was found to be gender-specific with males
having a greater amount of visceral fat, but less subcutaneous fat than females in
their respective groups. Independent of gender, survivors treated with CRT had a
higher percent body fat than survivors treated with chemotherapy alone due to
increased fat mass and decreased lean mass. Total fat mass was higher and
lean mass was lower in females than males (8).
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Similar to most medical conditions, individuals with pediatric ALL
experience different severities of the condition (2). Depending on the severity of
disease, the aggressiveness of treatment will vary. Therefore, the
aggressiveness of treatment and the influence on weight gain must also be
considered. Withycombe et al studied high risk, newly diagnosed children with
ALL who received more aggressive treatment than given to those with low risk
ALL (2). Researchers enrolled 1,638 high risk ALL patients who were treated on
the Children’s Cancer Group protocol CCG 1961 from November 1996 to May
2002 aged 2-20 years and determined weight patterns in order to identify factors
influenced body mass index (BMI) during treatment. The treatments used in this
protocol included vincristine, prednisone, daunomycin, asparaginase,
methotrexate, cytosine arabinoside, and cranial irradiation. The investigators
found a 14% incidence of obesity at diagnosis and 23% incidence at the end of
therapy. Thus, treatment of high risk ALL was linked with an increased frequency
of obesity but was similar to that of standard risk ALL patients. Other variables
associated with increased weight gain included female participants, being 5-9
years of age, obesity at diagnosis, being of Black or Hispanic race, and having
additional health issues such as grade 3 or 4 pancreas/glucose toxicity (2).
Though treatment with cranial irradiation in this study did not predict obesity,
other studies suggest that cranial irradiation of greater than 20 Gy is a significant
indicator in predicting obesity (2,5).
Robien et al. compared the usual dietary intake of adult survivors of
childhood ALL to the Dietary Approach to Stopping Hypertension (DASH) diet
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recommendations (9). A DASH diet concordance score was calculated to
determine patients compliance with dietary recommendations. Results showed
that patients followed the DASH diet guidelines for total and saturated fat intake,
but consumption of added sugars was more than double the recommendation.
These intakes were similar to that of the general population. Though compliance
with the DASH diet was not found to be associated with BMI or waist
circumference, poor compliance to the DASH diet made findings inconclusive (9).
Conclusion
In summary, many factors influence development of overweight and
obesity in pediatric ALL survivors. Factors known to be associated with increased
weight gain include age at diagnosis, being female, being overweight or obese at
baseline, receiving cranial radiation therapy, being treated with corticosteroids,
and being of Black or Hispanic race. To date no studies have evaluated the
impact of diet on the incidence of obesity in pediatric ALL survivors. Therefore,
the aim of this study was to evaluate the relationship between caloric and
macronutrient intake on the incidence of obesity in survivors of pediatric ALL.
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CHAPTER II
METHODS
Subjects
This retrospective study comprises analysis of existing data that was
collected for the Diminished Bone Mineral Density In Survivors Of Childhood
Acute Lymphoblastic Leukemia (ALL): A Severity-Adapted Clinical Trial (Bone II)
(10). Bone II was approved by the St. Jude Children’s Research Hospital Internal
Review Board. Participants consist of survivors of ALL (treated on Total XI, XII,
or XIII protocols) who were at least 5 years from completion of therapy and were
in first remission. All data was managed according to the Health Insurance
Portability and Accountability Act (HIPAA) of 1996.
Participant Grouping
Participants were grouped by BMI into the under/normal weight group and
the overweight/obese group for comparison. For children less than 20 years of
age, CDC growth charts and percentiles were used (11). Under/normal weight is
defined as being below the 85th percentile in weight for age, and
overweight/obesity was defined as being at of above the 85th percentile in weight
for age (12). For adults 20 years of age and older, BMI was used to assess
weight status. Under/normal weight was defined as a BMI of less than 25 kg/m²
and overweight/obesity was defined as 25 kg/m² and greater. BMI and growth
chart data for the participants was calculated at the time of the 24-hour recall
(11,12).
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Nutrient Analysis
Food records and macronutrient levels were evaluated to assess dietary
intake. Twenty-four hour food recall records collected during the first 6 months of
the study were retrieved from the existing data entered in the Nutrition Data
System for Research (NDSR) 2009 database. From these recalls, the amount of
food eaten, how it was prepared, and a detailed description of the food was used
to assess macronutrient intake. Macronutrient levels evaluated in this study
included: Kilocalories (kcal), grams of fat, percent kcal from fat, grams of
carbohydrates, percent kcal from carbohydrates, grams of sugar, grams of
protein, and percent kcal from protein. In addition to macronutrient levels, a
Healthy Eating Index (HEI) was also evaluated (13). The HEI is a measure that
compares dietary adherence to the Dietary Guidelines for Americans and
MyPyramid by using the amount of intake per 1,000 kilocalories. This index
evaluates nutrient intake based upon: total fruit (includes 100% juice), whole fruit
(not juice), total vegetables, dark green/orange vegetables/legumes, total grains,
whole grains, milk, meats and beans, oils, saturated fat, sodium, and calories
from solid fats/alcoholic beverages/added sugars. Patient scores were compared
to the mean scores from the U.S. population (13).
Data Analyses
Statistical analyses were performed using SAS statistical software (14).
The data collected was compared to the United States Department of Agriculture
(USDA) recommendations for healthy eating using Dietary Reference Intake
(DRI) and Acceptable Macronutrient Distribution Range (AMDR) based on
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age/gender. DRI is a measurement that uses Recommended Dietary Allowance
(RDA), Adequate Intake (AI), Estimated Energy Requirements (EER), and
Tolerable Upper Intake Levels (UL) to establish levels of macronutrients and
micronutrients needed daily to maintain a person’s health. AMDR is the range of
intake from an energy source such as fat, carbohydrates, and protein that is
associated with decreased risk of chronic disease development (15).
Demographic and treatment related variables were used to identify confounding
factors discussed in the background. Descriptive data included: BMI at
enrollment, age at diagnosis, ethnicity, gender, corticosteroid use, cranial
radiation therapy, and standard/high risk. Descriptive statistics were provided to
compare dietary intake to USDA recommendations. Wilcoxon’s rank sum test
was used to compare dietary intake between under/healthy weight survivors and
overweight/obese survivors. Fisher’s test and Chi-square test were also
performed for statistical analyses.
Inclusion Criteria
The inclusion criteria followed the same guidelines as the BONE II
protocol: survivors of ALL who were at least 5 years from completion of therapy,
were in first remission, and were treated on Total XI, XII, or XIII protocols (10).
For inclusion in the current study, participants must also have had a 24-hour food
recall obtained within the first 6 months from the start of the study, and
demographic and anthropometric data recorded.
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Exclusion Criteria
The exclusion criteria were any participants who were enrolled on the
BONE II protocol who did not have a 24-hr food recall obtained within the first 6
months of the study, or were missing demographic or anthropometric data.
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CHAPTER III
RESULTS
Patient Demographics
One hundred forty-six patients were enrolled for medical chart review; 4
were excluded due to missing 24-hour recalls within the first 6 months of BONE II
study enrollment. Five additional patients were excluded for missing patient
demographic and anthropometric data. Thus, final analysis included 137 patients.
Of the 137 participants eligible for the study, 91% were white, 7% black, 1%
Asian, and 1% were of other race. Gender was dispersed almost evenly with
55% being male and 45% being female.
Confounders Examined
Only 34% of patients enrolled received cranial radiation therapy with the
majority (66%) receiving 1,800 cGy and 34% receiving 2400 cGy. In examination
of risk categories, 16 of the 137 patients (11%) were missing risk category data,
but were not excluded from the study due to having all other data available. Of
the remaining participants, 63% were classified as high risk and 37% classified
as standard risk. While there was no statistical significance when comparing age
at diagnosis and likelihood of being overweight/obese, the median age of the
overweight/obese category was younger at diagnosis than the under/healthy
weight group with a median age of 3.5 years and 4.8 years, respectively. Also, all
participants received steroid therapy; however, steroid therapy differed
depending on time of enrollment and treatment protocol. Regardless, there was
no differentiation between obesity rates and type of steroid therapy received.
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Body Weight Status
BMI categories consisted of 82 participants (60%) in the under/healthy
weight category and 55 participants (40%) into the overweight/obese category.
Calorie and Macronutrient Intake
No statistical significance was observed in the comparison of calorie and
macronutrient intake with DRI/AMDR between the two BMI groups; however,
certain dietary behaviors were identified among participants. Ninety-four
participants (69%) were below the DRI for calorie intake while only 4% were
below the DRI for intake of protein and carbohydrates. Half the participants on
the study consumed above the AMDR for percentage of calories from fat, while
4% and 0% were above the AMDR for carbohydrate and protein, respectively. In
relation to percentage of calories derived from sugar (a form of carbohydrate),
96% of participants consumed above the AMDR. To clarify, the AMDR is based
on ranges, participants could meet protein and carbohydrate intake, exceed fat
intake, and still be below calorie needs. Descriptive statistics, anthropometrics,
and dietary intake of pediatric ALL survivors can be seen in Table 1, and the
AMDR ranges can be seen in Table 2. HEI was excluded from analysis due to
missing data.
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Table 1. Descriptive statistics, anthropometrics, and dietary intake of
pediatric ALL survivors
Variable
N
Min Median Max
Mean

Std
Dev
4.78
6.31
19.44
20.9
5.22
29.89
768.3
38.6
6.97
103.8
8.63

Age at diagnosis (yrs)
137 0.9
4.25 17.44
6.38
Age on study (yrs)
137 9.36
17.01 35.26
17.81
Height (cm)
137
78
157.6 190.6 156.19
Weight (kg)
137
11
57 115.5
57.89
BMI (kg/m^2)
137 12.2
21.8
39.6
23.04
Growth Chart Percentile
82*
1
73.5
98
66.09
Calories
137 791
2172
4819 2330.1
Fat (g)
137
18
86
250
93.04
% calories from fat
137
14
36
57
35.56
Carbohydrate (g)
137
85
286
708 292.09
% calories from
137
29
51
73
50.39
carbohydrate
Sugar (g)
137
11
146
301 149.15
60.9
% calories from sugar
137
6
26
57
26.03
9.16
Protein (g)
137
28
78
208
87.47
33.1
% calories from protein
137
6
15
27
15.28
3.92
*55 patients were from the adult group, and thus don’t have a growth chart
percentile
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Table 2. Acceptable Macronutrient Distribution Ranges based on gender and
age
Macronutrient
Age/Gender grouping
AMDR %
Fat
Males
9−13 y
25-35
14−18 y
25-35
19−30 y
25-35
31-50 y
25-35

Carbohydrates

Females
9−13 y
14−18 y
19−30 y
31-50 y
Males
9−13 y
14−18 y
19−30 y
31-50 y

25-35
25-35
25-35
25-35
45-65
45-65
45-65
45-65

Females
9−13 y
14−18 y
19−30 y
31-50 y
Sugar

Protein

45-65
45-65
45-65
45-65

There is no DRI for sugar intake but the USDA
recommends consuming no more than 6-10% of your
total calories from sugar.
Males
9−13 y
14−18 y
19−30 y
31-50 y

10-30
10-30
10-35
10-35

Females
9−13 y
14−18 y
19−30 y
31-50 y

10-30
10-30
10-35
10-35
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CHAPTER IV
DISCUSSION
Research and literature has shown that in the United States ALL is more
common in whites than blacks with the incidence of 3 out of every 4 cases
(16,17). Most occurrences of ALL occur between the ages of 2-5 years and occur
more often in males than females (18). This sample size rendered similar results
with median age at diagnosis of 4.25 years, and 55% of our sample consisting of
males. With respect to race, whites were slightly more prevalent in our study than
in the ALL population (90%).
When examining known confounders to BMI during ALL treatment, in
contrast to some published literature, no significant results were observed when
comparing BMI groups at enrollment to gender, race, CRT, steroid therapy, or
age at diagnosis (19). These results were not consistent with results from other
literature, which may be attributed to the limited sample size of the study (5-8).
Even though results were not significant, the median age at diagnosis for the
under/healthy weight group was 4.82 years while the overweight/obese group
was 3.49 years and was consistent with prior studies showing that the younger
the age at diagnosis the more likely to be overweight/obese (6).
Caloric and macronutrient intake was also compared to BMI at Bone II
enrollment. While no results were significant, some dietary trends among ALL
survivors were detected. Sixty-nine percent of study participants were below the
DRI for calorie intake. The interesting factor about this statistic is that the majority
of patients in both BMI groups were below the DRI for calories, 67% in the
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under/healthy weight group and 71% in the overweight/obese group. It is
common knowledge that excess calorie consumption will cause weight gain in
individuals, but our results were not indicative of this. It is possible there were
some additional confounders that were not examined that may have had an
influence. For instance, estimated calorie needs were based on DRI; however,
individuals with ALL may not have the same energy needs due to treatment
factors, such as hormonal and cranial radiation therapy, which may influence
metabolic function (7). On a positive note, even though most individuals were not
meeting caloric needs, 96% of participants met or exceeded the DRI for protein.
This data suggests that the focus on dietary intervention should be less about
consuming adequate protein and more focused on other criteria. Other variables
that exhibited a trend included percentage of calories from fat and percentage of
calories from sugar. The majority of participants consumed above the AMDR for
calories from fat, which suggests that participants on our study consumed too
many high fat foods during their 24-hour food recall; however, it does not
differentiate whether these fats were unsaturated or saturated. Also, an
astonishing 96% of participants were above the AMDR for percentage of calories
from sugar. This data implies that participants’ diets were derived too heavily
from sugar and may have been lacking in critical nutrients found in from other
sources of energy. Since 73% of participants were within the AMDR for
percentage of calories from carbohydrates and also consumed an excess
amount of sugar, foods containing other forms of carbohydrates may have been
lacking. Often, high sugar foods are lacking in fiber and other beneficial nutrients,

16

so participants in this study may have been consuming diets less than ideal for
good health. This indicates that dietary intervention should be more focused on
the amount and types of fats to consume and on limiting the consumption of high
sugar foods in the diet.
Limitations
Limitations include having a limited sample size, using 24-hour food
recalls to assess dietary intake, and using growth percentiles and BMI as a
measurement of fat mass. Having a limited sample size may not have given
enough data to accurately assess confounders and/or dietary behaviors in
comparison to BMI at Bone II enrollment. This study also does not accurately
portray results across all races and ethnicities. The sample size used contained
90% whites and data represented in literature associates only 75% of ALL cases
occurring in whites (16,17). Therefore, our results may not be consistent among
all ALL survivors. Using 24-hour food recalls may not accurately represent an
individual’s actual dietary intake since it is simply a snap shot of an individual’s
diet based on recollection of what food what consumed, how it was prepared,
what amount was consumed, and how closely the item eaten was to what was
entered into the food analysis software. In addition, due to the fact that
participants on our study were seen outpatient, many of them were traveling on
the days that the 24-hour food recall was taken. Therefore, this record may not
have been reflective of the participants’ usual dietary intake. Using food
frequency questionnaires or three day food records to better encompass
individuals usual dietary intake may help get a better idea of how an individual
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actually eats. Also, having to eliminate the HEI from the study affected the ability
to not only assess caloric and macronutrient levels, but also how healthy the diet
was in comparison to the U.S. population. Another limitation involved how weight
status was assessed. When using growth percentiles and BMI as a
measurement weight status it doesn’t differentiate between fat and lean tissue
and may not accurately assess an individual being overweight or obese. In future
studies using bioelectric impedance, dual x-ray absorptiometry, air displacement
plethysmography, or hydrostatic weighing may better distinguish the effects of
diet on weight status.
Conclusion
In summary, based on these findings there is no association between
obesity status at enrollment and caloric and macronutrient intake (as compared
with AMDR/DRI). However, dietary trends of ALL survivors observed from this
data showed participants were more likely to be below the DRI for calories
regardless of BMI group, most participants met or exceeded the DRI for protein
and carbohydrate intake, over half the participants consumed above the AMDR
for percentage of calories from fat, and almost every participant consumed above
the AMDR for percentage of calories from sugar. Additional research still needs
to be done to determine whether caloric and macronutrient intake are associated
with the incidence of obesity using larger samples, better measures to assess
weight status, and using food frequency questionnaires or three day food records
to assess usual dietary intake. The long term effects of ALL treatment and diet on
the incidence of obesity is still lacking research; however, survivors may benefit
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from dietary intervention after completion of therapy to help educate on the
benefits of consuming a healthy diet and its impact on quality of life and BMI
status.
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APPENDICIES

APPENDIX A
GUIDELINES FOR HEALTHY EATING
Macronutrient

Age/Gender
grouping

DRI in
grams/day

Calories

Males*
0-6 months
6 months-1 year
1-3
4-8
9-13
14-18
19-30
31-50
>50

570
743
1046
1742
2279
3152
3067
3067
3067

Female*
0-6 months
6 months-1 year
1-3
4-8
9-13
14-18
19-30
31-50
>50

520
676
992
1642
2071
2368
2403
2403
2403

*For males,
subtract 10
calories per day
for each year of
age above 19
*For females,
subtract 7 calories
per day for each
year above 19
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Acceptable
Macronutrient
Distribution
Range (%)
Category not
applicable for
calories

